Abstract:Introduction: Evasion of the immune system is a hallmark of cancer and understanding immune escape mechanisms has led to the development of immunotherapies to boost anti-tumor immunity. CD47 is an immunosuppressive protein that transduces a "don't eat me" signal when bound to the SIRPα receptor on antigen presenting cells (APCs). Cancer cells exploit CD47 to block phagocytosis by APCs and dampen anti-tumor immune responses. Various inhibitors of the CD47-SIRPα signaling axis, including monoclonal antibodies, have been developed as immunotherapeutic agents for administering CD47 blockade in cancer patients, and are currently being evaluated in clinical trials. Understanding mechanisms of tumor resistance to CD47-targeted immunotherapy will guide its clinical development and could inform rational combination therapies to enhance its efficacy. Since CD47 is prognostically and functionally relevant in non-small cell lung cancer (NSCLC), we investigated the response of two syngeneic, murine lung cancer models to CD47 loss-of-function (LOF). Methods: CRISPR/Cas9 was used to knockout (KO) CD47 in two murine (LLC, CMT167) syngeneic models of NSCLC. Tumor growth studies were conducted in immune competent (C57BL/6) mice orthotopically implanted with wildtype (WT) or CD47 KO cells. Immunophenotyping of tumors was done prior to humane endpoints using flow cytometry to compare immune cell infiltration in WT versus CD47 KO tumors to assess lung tumor response to CD47 LOF. Results: Survival analyses of immunocompetent hosts with orthotopic LLC and CMT tumors revealed that mice with CD47 KO tumors lived longer than those with WT tumors, although CD47 KO tumors were ultimately lethal. Tumor immunophenotyping revealed higher frequencies of MHC-IIhighCD80+ M1 macrophages and activated cytotoxic CD69+CD8+ T cells in CD47 KO tumors compared to WT. Moreover, the percentage of PD-L1+ tumor and myeloid cells was greater in CD47 KO tumors compared to WT tumors, suggesting PD-L1 may be upregulated on various cell types in the TME as a compensation mechanism when CD47 is inhibited. Conclusion: Consistent with the literature, our findings show that CD47 LOF in lung cancer cells prolongs the survival of tumor-bearing mice and promotes infiltration of anti-tumor immune cells in two orthotopic, syngeneic NSCLC models. Upregulation of PD-L1 in cancer and myeloid cells from CD47 KO tumors was also observed, revealing a putative PD-L1-driven mechanism of resistance to CD47 blockade. Although additional preclinical and clinical studies are needed to confirm the generalizability of our observations and to validate them in patients treated with CD47-targeted therapy, our findings provide evidence to support continued development of approaches for combining CD47 and PD-L1 blockade as an effective immunotherapeutic strategy for the treatment of NSCLC. Citation Format: Asa P.Y Lau, Kelsie L Thu. Upregulation of PD-L1 as a mechanism of resistance to CD47 inhibition in non-small cell lung cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B007.

Silencing EGFR-upregulated Expression of CD55 and CD59 Activates the Complement System and Sensitizes Lung Cancer to Checkpoint Blockade

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47

Integrative transcriptome analysis reveals the molecular events underlying impaired T-cell responses in EGFR-mutant lung cancer

CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis

Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer

EGFR‐Induced and c‐Src‐Mediated CD47 Phosphorylation Inhibits TRIM21‐Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion

EGFR inhibition in EGFR‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment

EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer

CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma

Data from Autocrine Complement Inhibits IL10-Dependent T-cell–Mediated Antitumor Immunity to Promote Tumor Progression

The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment

CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer

EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer

Abstract B007: Upregulation of PD-L1 as a mechanism of resistance to CD47 inhibition in non-small cell lung cancer

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target

Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8+ T Cells Cytotoxicity

EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer